Drug Profile
Risperidone - Mapi Pharma
Alternative Names: Risperidone LAI; Risperidone LAI - Mapi Pharma; Risperidone LAI+Latest Information Update: 22 Sep 2023
Price :
$50
*
At a glance
- Originator Mapi Pharma
- Developer Jiangsu Nhwa Pharmaceutical; Mapi Pharma
- Class Antidepressants; Antineoplastics; Antipsychotics; Behavioural disorder therapies; Fluorinated hydrocarbons; Isoxazoles; Mood stabilisers; Piperidines; Pyrimidinones; Small molecules
- Mechanism of Action Dopamine D2 receptor antagonists; Serotonin 2A receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Bipolar disorders; Schizophrenia
Most Recent Events
- 22 Sep 2023 Discontinued - Phase-I for Schizophrenia in China (IV) (Mapi Pharma pipeline, September 2023)
- 22 Sep 2023 Discontinued - Preclinical for Bipolar disorders in China, Israel (IV) (Mapi Pharma pipeline, September 2023)
- 22 Sep 2023 Discontinued - Preclinical for Schizophrenia in Israel (IV) (Mapi Pharma pipeline, September 2023)